Skip to content

Study · Randomized controlled trial · n = 1,554 · 2008

7 results

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU

Journal of clinical oncology : official journal of the American Society of Clinical Oncology14 Apr 2008Cited by 479 (Europe PMC)

PMID18413638 (opens in a new tab)DOI10.1200/jco.2007.14.9021 (opens in a new tab)PepBankPUB-18413638
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In locally advanced prostate cancer, additional goserelin improved disease-free survival to 22.5% versus 13.2% (P < .0001).

    In plain wordsIn locally advanced prostate cancer, longer goserelin treatment improved disease-free survival compared with short-term treatment.

    Peptide
    Goserelin
    Outcome
    IncreaseDisease-free survival at 10 years
    Study

    n = 1,554

    Comparator
    Short-term ADT plus radiotherapy
    Outcome group
    Cancer Survival · Cancer
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Disease-free survival at 10 years
    13.2%
    STAD + RT
    Disease-free survival at 10 years
    22.5%
    LTAD + RT
    P value
    < 0.0001 unitless
    disease-free survival at 10 years, LTAD + RT vs STAD + RT

    Source sentences

    Summary
    At 10 years, the LTAD + RT group showed significant improvement over the STAD + RT group for all end points except overall survival: disease-free survival (13.2% v 22.5%; P < .0001)
    3 context sentences
    Summary · context
    Prostate cancer patients with T2c-T4 prostate cancer with no extra pelvic lymph node involvement and prostate-specific antigen (PSA) less than 150 ng/mL were included.
    Summary · context
    All patients received 4 months of goserelin and flutamide before and during RT.
    Summary · context
    They were randomized to no further ADT (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In locally advanced prostate cancer, additional goserelin improved disease-specific survival to 88.7% versus 83.9% (P = .0042).

    In plain wordsIn locally advanced prostate cancer, longer goserelin treatment improved disease-specific survival compared with short-term treatment.

    Peptide
    Goserelin
    Outcome
    IncreaseDisease-specific survival at 10 years
    Study

    n = 1,554

    Comparator
    Short-term ADT plus radiotherapy
    Outcome group
    Cancer Survival · Cancer
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Disease-specific survival at 10 years
    83.9%
    STAD + RT
    Disease-specific survival at 10 years
    88.7%
    LTAD + RT
    P value
    0.0042 unitless
    disease-specific survival at 10 years, LTAD + RT vs STAD + RT

    Source sentences

    Summary
    disease-specific survival (83.9% v 88.7%; P = .0042)
    3 context sentences
    Summary · context
    Prostate cancer patients with T2c-T4 prostate cancer with no extra pelvic lymph node involvement and prostate-specific antigen (PSA) less than 150 ng/mL were included.
    Summary · context
    All patients received 4 months of goserelin and flutamide before and during RT.
    Summary · context
    They were randomized to no further ADT (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In locally advanced prostate cancer, additional goserelin reduced local progression to 12.3% versus 22.2% (P < .0001).

    In plain wordsIn locally advanced prostate cancer, longer goserelin treatment reduced local progression compared with short-term treatment.

    Peptide
    Goserelin
    Outcome
    DecreaseLocal progression at 10 years
    Study

    n = 1,554

    Comparator
    Short-term ADT plus radiotherapy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Local progression at 10 years
    22.2%
    STAD + RT
    Local progression at 10 years
    12.3%
    LTAD + RT
    P value
    < 0.0001 unitless
    local progression at 10 years, LTAD + RT vs STAD + RT

    Source sentences

    Summary
    local progression (22.2% v 12.3%; P < .0001)
    3 context sentences
    Summary · context
    Prostate cancer patients with T2c-T4 prostate cancer with no extra pelvic lymph node involvement and prostate-specific antigen (PSA) less than 150 ng/mL were included.
    Summary · context
    All patients received 4 months of goserelin and flutamide before and during RT.
    Summary · context
    They were randomized to no further ADT (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In locally advanced prostate cancer, additional goserelin reduced distant metastasis to 14.8% versus 22.8% (P < .0001).

    In plain wordsIn locally advanced prostate cancer, longer goserelin treatment reduced distant metastasis compared with short-term treatment.

    Peptide
    Goserelin
    Outcome
    DecreaseDistant metastasis at 10 years
    Study

    n = 1,554

    Comparator
    Short-term ADT plus radiotherapy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Distant metastasis at 10 years
    22.8%
    STAD + RT
    Distant metastasis at 10 years
    14.8%
    LTAD + RT
    P value
    < 0.0001 unitless
    distant metastasis at 10 years, LTAD + RT vs STAD + RT

    Source sentences

    Summary
    distant metastasis (22.8% v 14.8%; P < .0001)
    3 context sentences
    Summary · context
    Prostate cancer patients with T2c-T4 prostate cancer with no extra pelvic lymph node involvement and prostate-specific antigen (PSA) less than 150 ng/mL were included.
    Summary · context
    All patients received 4 months of goserelin and flutamide before and during RT.
    Summary · context
    They were randomized to no further ADT (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In locally advanced prostate cancer, additional goserelin reduced biochemical failure to 51.9% versus 68.1% (P <or= .0001).

    In plain wordsIn locally advanced prostate cancer, longer goserelin treatment reduced biochemical failure compared with short-term treatment.

    Peptide
    Goserelin
    Outcome
    DecreaseBiochemical failure at 10 years
    Study

    n = 1,554

    Comparator
    Short-term ADT plus radiotherapy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Biochemical failure at 10 years
    68.1%
    STAD + RT
    Biochemical failure at 10 years
    51.9%
    LTAD + RT

    Source sentences

    Summary
    biochemical failure (68.1% v 51.9%; P <or= .0001)
    3 context sentences
    Summary · context
    Prostate cancer patients with T2c-T4 prostate cancer with no extra pelvic lymph node involvement and prostate-specific antigen (PSA) less than 150 ng/mL were included.
    Summary · context
    All patients received 4 months of goserelin and flutamide before and during RT.
    Summary · context
    They were randomized to no further ADT (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In locally advanced prostate cancer, overall survival was 53.9% versus 51.6% with additional goserelin (P = .36).

    In plain wordsIn locally advanced prostate cancer, overall survival did not significantly differ between longer and short-term goserelin treatment.

    Peptide
    Goserelin
    Outcome
    No significant changeOverall survival at 10 years
    Study

    n = 1,554

    Comparator
    Short-term ADT plus radiotherapy
    Outcome group
    Cancer Survival · Cancer
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Overall survival at 10 years
    51.6%
    STAD + RT
    Overall survival at 10 years
    53.9%
    LTAD + RT

    Source sentences

    Summary
    and overall survival (51.6% v 53.9%, P = .36).
    3 context sentences
    Summary · context
    Prostate cancer patients with T2c-T4 prostate cancer with no extra pelvic lymph node involvement and prostate-specific antigen (PSA) less than 150 ng/mL were included.
    Summary · context
    All patients received 4 months of goserelin and flutamide before and during RT.
    Summary · context
    They were randomized to no further ADT (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In prostate cancers with Gleason scores of 8 to 10, additional goserelin improved overall survival to 45.1% versus 31.9% (P = .0061).

    In plain wordsIn high-grade prostate cancer, longer goserelin treatment improved overall survival compared with short-term treatment.

    Peptide
    Goserelin
    Outcome
    IncreaseOverall survival in Gleason 8 to 10 subgroup
    Study

    n: not reported in source

    Comparator
    Short-term ADT plus radiotherapy
    Outcome group
    Cancer Survival · Cancer
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Overall survival at 10 years, Gleason 8 to 10 subgroup
    31.9%
    STAD + RT
    Overall survival at 10 years, Gleason 8 to 10 subgroup
    45.1%
    LTAD + RT

    Source sentences

    Summary
    An overall survival difference was observed (31.9% v 45.1%; P = .0061), as well as in all other end points herein.
    4 context sentences
    Summary · context
    One subgroup analyzed consisted of all cancers with a Gleason score of 8 to 10 cancers.
    Summary · context
    Prostate cancer patients with T2c-T4 prostate cancer with no extra pelvic lymph node involvement and prostate-specific antigen (PSA) less than 150 ng/mL were included.
    Summary · context
    All patients received 4 months of goserelin and flutamide before and during RT.
    Summary · context
    They were randomized to no further ADT (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00767286

Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Radiation Therapy Oncology GroupCompletion Nov 2003

Prostate Cancer

Trial pageClinicalTrials.govUpdated 28 Jan 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.